Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Express Scripts
Boehringer Ingelheim
US Army
UBS
Mallinckrodt
Colorcon
Teva

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,235,247

« Back to Dashboard

Which drugs does patent 7,235,247 protect, and when does it expire?

Patent 7,235,247 protects OMNARIS and is included in one NDA.

This patent has forty-eight patent family members in thirty-five countries.
Summary for Patent: 7,235,247
Title:Pharmaceutical composition for application to mucosa
Abstract:The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, a medicament, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high permeability to the blood at the mucosa. The present invention further provides a pharmaceutical composition for application to the mucosa comprising a hemostatic agent and a medicament. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to permeability and retentivity at the mucosa.
Inventor(s): Nishibe; Yoshihisa (Hino, JP), Kinoshita; Wataru (Hino, JP), Kawabe; Hiroyuki (Tokyo, JP)
Assignee: Teijin Pharma Limited (Tokyo, JP)
Application Number:10/201,303
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 7,235,247

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,235,247

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10-110887Apr 21, 1998
Japan10-110888Apr 21, 1998

Non-Orange Book US Patents Family Members for Patent 7,235,247

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,939,559 Pharmaceutical composition for application to mucosa ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Express Scripts
US Army
Medtronic
Healthtrust
UBS
US Department of Justice
Fish and Richardson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.